3 Magnificent S&P 500 Stocks Down Between 16% and 21% to Buy on the Dip
Despite all of the recent mayhem, the market has nearly returned to all-time highs.
Even with this run-up in price, some of my favorite S&P 500 stocks didn't go along for the ride.
Now looks like the perfect time to consider these top-tier compounders -- all down from their highs.
10 stocks we like better than Copart ›
And just like that, the S&P 500 index is nearing all-time highs again.
As unlikely as this may have seemed two months ago, the stock market dismissed numerous fears and pushed many growth stocks to new highs. However, not all S&P 500 stocks took part in this recovery. This notion is particularly true for many "steady Eddie" compounders in the index.
Today, we'll look at three of these magnificent compounders down between 16% and 21% and discuss why each looks like an excellent buy over the long term.
Copart (NASDAQ: CPRT) owns roughly 250 salvage yards across North America and processes the sale of over 3 million (mostly) totaled vehicles on its online auction platform. The company generates 81% of its sales from car insurers, who use Copart's platform to sell totaled vehicles to dismantlers, exporters, car repair shops, dealerships, or the general public.
The Texas-based company holds nearly half of the market share in this salvage vehicle niche and operates in a duopoly alongside RB Global. However, whereas RB Global leases the land for most of its salvage yards, Copart owns almost all of its property, giving the latter a significant advantage in profitability.
Furthermore, the company benefits from NIMBY (not in my backyard) feelings from citizens who don't want to see more junkyards in their towns. This sentiment, combined with Copart's nationwide network of locations and top-tier profitability, provides the company with a wide moat. As result, Copart has been a 330-bagger since its initial public offering in 1994.
With this success, though, comes a lofty valuation. And in the company's last quarter, Copart slightly missed analysts' expectations, prompting a 21% sell-off. Following this decline, however, the company trades at a more reasonable 27 times cash from operations -- a mark it hadn't seen in over two years.
Ultimately, Copart is well-positioned to thrive over the long term, in my opinion. As cars become increasingly complex and more technologically advanced, their repair costs will also continue to rise. With insurers more likely to deem a car "totaled" after an accident -- rather than face these ballooning repair costs -- Copart stands to benefit, just as it has for over three decades.
Much like Copart, rural lifestyle retailer Tractor Supply Company (NASDAQ: TSCO) went public in 1994 and has rewarded investors by becoming a 219-bagger since then. Home to around 2,300 Tractor Supply stores and 206 Petsense locations, the company is a nationwide chain catering to an often-overlooked rural segment of the population.
With the company focused solely on serving these communities, it is perhaps no surprise that it has a massive and loyal customer base. Its Neighbor's Rewards Club has grown from 15 million members in 2019 to nearly 40 million today. What's truly remarkable about these members, however, is that they account for a stunning 80% of Tractor Supply's sales.
This ability to turn new guests into repeat purchasers highlights the company's value proposition to members and establishes a "sticky" base of steady sales. Furthermore, with most of Tractor Supply's revenue coming from CUE (consumable, usable, or edible) categories, the company generates frequent visits from members. The repeat nature of these sales makes Tractor Supply less volatile than discretionary retail stocks, which are more susceptible to fluctuations in consumer confidence.
Despite these promising attributes, Tractor Supply's shares have slid 16% over the last year as its sales growth slowed to 2% amid a challenging environment.
Ultimately, though, if we zoom out and look at the longer term, I believe Tractor Supply offers numerous market-beating catalysts, including:
Management's goal to grow its store count to 3,200
Reaching the 55 million-member mark by 2029
Growth in its nascent direct sales and pet and animal prescription businesses
The expansion of its private label products and retail media operations
Management's goal to reduce its share count by 1% to 2% annually
A well-funded and growing dividend yielding around 1.5%
Trading at 25 times earnings, Tractor Supply is a top-tier operator poised to continue dominating its niche -- all at a sub-market valuation.
Public safety leader Motorola Solutions (NYSE: MSI) not only offers multiple layers of safety to its customers, but also to its investors. Motorola operates via three product categories:
Land mobile radio (LMR) communications: These 13,000 LMR networks across the globe are mission-critical communication infrastructure, whether it is a firefighter's walkie-talkie or the networks used if cell towers go down in a natural disaster.
Video security and access control equipment: Over 5 million fixed cameras with artificial intelligence analytics deployed, alongside mobile video solutions such as body cameras and automated license plate readers.
Command center solutions: Motorola's software is used by 60% of the 911 call centers in the United States for call routing and handling, dispatch and records, and general workflow collaboration within the department.
Thanks to the essential nature of its products and its leadership in each niche, Motorola has a wide moat around its business. Powered by this moat and the company's strong cash generation, Motorola has been a 10-bagger in the last 15 years.
However, after the company's revenue growth slowed to 6% over the last two quarters while management issued softer guidance for the year, its shares dropped 19% from their highs. I believe this sell-off could be overdone, though, with Motorola now trading at a more palatable 31 times free cash flow.
The primary reason I'm bullish on the company's long-term potential is its excellent track record as a serial acquirer, having completed 30 acquisitions for approximately $7 billion since 2015. Maintaining a lofty cash return on invested capital of 31%, Motorola excels at generating substantial returns from the debt and equity it uses to make its purchases.
Now eyeing a $4.4 billion takeout of Silvus Technologies and its mobile ad-hoc networks, Motorola looks to build upon its leading communications operations and continue beating the market as it goes.
Before you buy stock in Copart, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Copart wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!*
Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Josh Kohn-Lindquist has positions in Copart. The Motley Fool has positions in and recommends Copart, Home Depot, and Tractor Supply. The Motley Fool recommends the following options: short July 2025 $54 calls on Tractor Supply. The Motley Fool has a disclosure policy.
3 Magnificent S&P 500 Stocks Down Between 16% and 21% to Buy on the Dip was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
14 minutes ago
- Associated Press
Hall of Famer Dale Earnhardt Jr. wins NASCAR national series debut as crew chief at Pocono
LONG POND, Pa. (AP) — Dale Earnhardt Jr. might already be NASCAR's most popular crew chief. He's certainly an undefeated one. Pressed into unexpected service, Earnhardt called the shots for 18-year-old prospect Connor Zilisch in the No. 88 Chevrolet and they landed in victory lane Saturday in the second-tier Xfinity Series race at Pocono Raceway. 'We had a lot of things going our way,' Earnhardt said. Earnhardt — who won NASCAR's most-popular driver award 15 times — made a pit stop from his day job as team owner at JR Motorsports with normal crew chief Mardy Lindley suspended one race because of a lug nut infraction this month at Nashville. Aside from his duties as team owner, Earnhardt also was at Pocono for his role on the Prime broadcast for the NASCAR Cup Series race Sunday. 'Lot of fun for me today,' Earnhardt said. 'I missed the thrill of competition. I love broadcast, don't get me wrong. But nothing compares to driving or just being part of the team. Being an owner doesn't really deliver like this. This is a lot of fun.' Earnhardt had his wife and two young daughters in tow with him as he made the celebratory walk to victory lane. Oldest daughter Isla Rose clutched the checkered flag while youngest Nicole Lorraine soaked in the scene from her dad's arms. The win continued a banner season for the NASCAR Hall of Fame driver — who swept two races at Pocono as a driver in 2014 — after JR Motorsports and reigning Xfinity Series champion Justin Allgaier qualified for the season-opening Daytona 500 and secured their Cup Series debut. Earnhardt won two Daytona 500s, in 2004 and 2014, and 26 races overall. His side hustle Saturday was made a bit easier with Zilisch behind the wheel. Zilisch, who turns 19 in July, raced to his second Xfinity victory of the season and third of his young career. He won his Xfinity debut last year at Watkins Glen International. Earnhardt even pitched in during the race and tossed tires over the wall during pit stops. Zilisch took the win down to the wire and finally passed Jesse Love with five laps left in the race. Love finished second. 'Dale Junior, not too bad on the box,' Zilisch said. 'Pretty cool to have him up there. Getting him a 1-for-1 win as crew chief is pretty awesome.' ___ AP auto racing:
Yahoo
18 minutes ago
- Yahoo
Investors in Catapult Group International (ASX:CAT) have seen incredible returns of 656% over the past three years
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. One such superstar is Catapult Group International Ltd (ASX:CAT), which saw its share price soar 656% in three years. Also pleasing for shareholders was the 63% gain in the last three months. We love happy stories like this one. The company should be really proud of that performance! So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Catapult Group International isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Over the last three years Catapult Group International has grown its revenue at 14% annually. That's pretty nice growth. Some shareholders might think that the share price rise of 96% per year is a lucky result, considering the level of revenue growth. A hot stock like this is usually well worth taking a closer look at, as long as you don't let the fear of missing out (FOMO) impact your thinking. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. We're pleased to report that Catapult Group International shareholders have received a total shareholder return of 203% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 38% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Catapult Group International , and understanding them should be part of your investment process. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
19 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
